Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.

Systemic short chain fatty acids limit antitumor effect of CTLA-4 blockade in hosts with cancer

Open access

Abstract

Gut microbiota composition influences the clinical benefit of immune checkpoints in patients with advanced cancer but mechanisms underlying this relationship remain unclear. Molecular mechanism whereby gut microbiota influences immune responses is mainly assigned to gut microbial metabolites. Short-chain fatty acids (SCFA) are produced in large amounts in the colon through bacterial fermentation of dietary fiber. We evaluate in mice and in patients treated with anti-CTLA-4 blocking mAbs whether SCFA levels is related to clinical outcome. High blood butyrate and propionate levels are associated with resistance to CTLA-4 blockade and higher proportion of Treg cells. In mice, butyrate restrains anti-CTLA-4-induced up-regulation of CD80/CD86 on dendritic cells and ICOS on T cells, accumulation of tumor-specific T cells and memory T cells. In patients, high blood butyrate levels moderate ipilimumab-induced accumulation of memory and ICOS + CD4 + T cells and IL-2 impregnation. Altogether, these results suggest that SCFA limits anti-CTLA-4 activity.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41467-020-16079-x

Cites

54 of 54 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Baseline gut microbiota composition in patients with MM. a Relative abundance of dominant (>1% of total reads) gut microbial genera are represented for each patient at V1 (baseline, n = 38). b Histograms of relative abundance of eight genera at baseline between poor (PB) and long-term clinical benefit (LTB) patients. Mann–Whitney two-tailed tests were used. p-values are indicated on each graph. c Histograms of relative abundance of Faecalibacterium according to overall survival (OS over 18 months (OS > 18 m) and OS under 18 months (OS < 18 m)) in patients. Mann–Whitney two-tailed tests were used. p-values are indicated on the graph. d, Kaplan–Meier curve of progression-free survival (PFS) of patients classified into two groups according to the median relative abundance of Faecalibacterium (n = 38). Log-rank (mantel-cox) test was used. e Pearson correlation between the relative abundance of Faecalibacterium assessed by 16S rDNA analysis (% of total reads NGS) and Q-PCR (% Q-PCR) analyses on feces at baseline (n = 24). r and p values are indicated on each graph. ns, not significant.
Fig. 1 Baseline gut microbiota composition in patients with MM. a Relative abundance of dominant (>1% of total reads) gut microbial genera are represented for each patient at V1 (baseline, n = 38). b Histograms of relative abundance of eight genera at baseline between poor (PB) and long-term clinical benefit (LTB) patients. Mann–Whitney two-tailed tests were used. p-values are indicated on each graph. c Histograms of relative abundance of Faecalibacterium according to overall survival (OS over 18 months (OS > 18 m) and OS under 18 months (OS < 18 m)) in patients. Mann–Whitney two-tailed tests were used. p-values are indicated on the graph. d, Kaplan–Meier curve of progression-free survival (PFS) of patients classified into two groups according to the median relative abundance of Faecalibacterium (n = 38). Log-rank (mantel-cox) test was used. e Pearson correlation between the relative abundance of Faecalibacterium assessed by 16S rDNA analysis (% of total reads NGS) and Q-PCR (% Q-PCR) analyses on feces at baseline (n = 24). r and p values are indicated on each graph. ns, not significant.CC BY · PubMed Central
Fig. 2 Association between F. prausnitzii, systemic concentrations of SCFA and clinical outcomes. a Quantity Mean 16S/ng DNA of F. prausnitzii and B. fragilis at baseline (Q-PCR). Each patient’s microbiota is presented in the graph (n = 38). 0–6 M: overall survival ranging from 0 to 6 months (n = 4), >6–18 M: overall survival ranging from 6 to 18 months (n = 23), >18 M: overall survival >18 months (n = 11). Two-Way ANOVA followed by Tukey’s tests for multiple comparisons was performed. p-values are indicated on each graph; ns, not significant. b Kaplan–Meier survival curves of PFS of patients classified into two groups according to median of F. prausnitzii/ng DNA (Low vs high F. prau; left panel) and 16S BACTERIA/ ng DNA (low vs high Bacteria; right panel). Date were performed using Q-PCR analyses on feces at baseline (n = 38), Log-rank (mantel-cox) test was used c Spearman correlation between the relative abundance of Firmicutes assessed by 16S DNA analysis (% of total reads NGS) and serum butyrate at baseline (n = 33). d Q-PCR analyses on feces at baseline of F. prausnitzii (16S F.prau/ng DNA) according to the median concentrations of serum acetate, propionate and butyrate (n = 33). e As in (d) but proportion (n = 33). Each dot represents a mean quantity (assessed in duplicate for each sample) for one patient. Two-tailed Mann–Whitney tests were used (d, e). p-values are indicated on each graph; ns, not significant. Kaplan–Meier survival curves of PFS according to the median value of serum propionate (left panels) and butyrate (right panels) concentrations in French (f, n = 40) and Italian (g, n = 45) cohort, Log-rank (mantel-cox) test was used. h Pearson correlations between serum concentrations of acetate, butyrate and propionate and PFS (n = 40) in French cohort; i As in (h) but for OS (n = 40) in French cohort. Each dot represents one patient. p and r are indicated on each graph.
Fig. 2 Association between F. prausnitzii, systemic concentrations of SCFA and clinical outcomes. a Quantity Mean 16S/ng DNA of F. prausnitzii and B. fragilis at baseline (Q-PCR). Each patient’s microbiota is presented in the graph (n = 38). 0–6 M: overall survival ranging from 0 to 6 months (n = 4), >6–18 M: overall survival ranging from 6 to 18 months (n = 23), >18 M: overall survival >18 months (n = 11). Two-Way ANOVA followed by Tukey’s tests for multiple comparisons was performed. p-values are indicated on each graph; ns, not significant. b Kaplan–Meier survival curves of PFS of patients classified into two groups according to median of F. prausnitzii/ng DNA (Low vs high F. prau; left panel) and 16S BACTERIA/ ng DNA (low vs high Bacteria; right panel). Date were performed using Q-PCR analyses on feces at baseline (n = 38), Log-rank (mantel-cox) test was used c Spearman correlation between the relative abundance of Firmicutes assessed by 16S DNA analysis (% of total reads NGS) and serum butyrate at baseline (n = 33). d Q-PCR analyses on feces at baseline of F. prausnitzii (16S F.prau/ng DNA) according to the median concentrations of serum acetate, propionate and butyrate (n = 33). e As in (d) but proportion (n = 33). Each dot represents a mean quantity (assessed in duplicate for each sample) for one patient. Two-tailed Mann–Whitney tests were used (d, e). p-values are indicated on each graph; ns, not significant. Kaplan–Meier survival curves of PFS according to the median value of serum propionate (left panels) and butyrate (right panels) concentrations in French (f, n = 40) and Italian (g, n = 45) cohort, Log-rank (mantel-cox) test was used. h Pearson correlations between serum concentrations of acetate, butyrate and propionate and PFS (n = 40) in French cohort; i As in (h) but for OS (n = 40) in French cohort. Each dot represents one patient. p and r are indicated on each graph.CC BY · PubMed Central
Fig. 3 Sodium butyrate diminished antitumor efficacy of CTLA-4 blockade in mice. a Experimental setting. b Tumor growth of CT26 in Balb/c mice. White circles anti-CTLA-4 (aCTLA-4; clone 9D9) + water (n = 19); Black circles isotype control (IgG2b; clone MPC-11) + water (n = 19); white squares anti-CTLA-4 (aCTLA-4) + sodium butyrate in drinking water (n = 20); black squares isotype control + sodium butyrate in drinking water (n = 20); **p = 0.0029 and ****p < 0.0001. c % of survival in each group at each day of the experiment. d As in (b), but median tumor size (mm2 +/− SEM) at Day 20 in each group. e As in (b) but, CT26 tumor size over time after tumor inoculation in each group. Each line represents one mouse. Complete responses (CR) are indicated on each graph. f Tumor growth of MC38 in C57/Bl6 mice (n = 10 per group); **p = 0.0098 and ***p = .0002. g As in (f) but median tumor size (mm2 +/− SEM) at Day 16 in each group. h Tumor growth of MCA101OVA in C57/Bl6 mice (n = 9 (Isotype + water and aCTLA-4+water) or 10 (Butyrate + water and aCTLA-4+butyrate) per group); ***p = 0.0001. Each dot represents one mouse; a pool of two independent experiments is shown (b, c, d and e); one representative experiment out of two experiments is shown (f and h). Two-way ANOVA was used (b, f, g and h); Log-rank (Mantel-Cox) test was used for comparison of two-to-two survival curves (c). Only aCTLA-4 +water and Isotype + water p-values are shown on the graphs (b, f and h). Mann Whitney (two-tailed) test was used (d, g). Exact p-values are indicated on each graph; ns, not significant.
Fig. 3 Sodium butyrate diminished antitumor efficacy of CTLA-4 blockade in mice. a Experimental setting. b Tumor growth of CT26 in Balb/c mice. White circles anti-CTLA-4 (aCTLA-4; clone 9D9) + water (n = 19); Black circles isotype control (IgG2b; clone MPC-11) + water (n = 19); white squares anti-CTLA-4 (aCTLA-4) + sodium butyrate in drinking water (n = 20); black squares isotype control + sodium butyrate in drinking water (n = 20); **p = 0.0029 and ****p < 0.0001. c % of survival in each group at each day of the experiment. d As in (b), but median tumor size (mm2 +/− SEM) at Day 20 in each group. e As in (b) but, CT26 tumor size over time after tumor inoculation in each group. Each line represents one mouse. Complete responses (CR) are indicated on each graph. f Tumor growth of MC38 in C57/Bl6 mice (n = 10 per group); **p = 0.0098 and ***p = .0002. g As in (f) but median tumor size (mm2 +/− SEM) at Day 16 in each group. h Tumor growth of MCA101OVA in C57/Bl6 mice (n = 9 (Isotype + water and aCTLA-4+water) or 10 (Butyrate + water and aCTLA-4+butyrate) per group); ***p = 0.0001. Each dot represents one mouse; a pool of two independent experiments is shown (b, c, d and e); one representative experiment out of two experiments is shown (f and h). Two-way ANOVA was used (b, f, g and h); Log-rank (Mantel-Cox) test was used for comparison of two-to-two survival curves (c). Only aCTLA-4 +water and Isotype + water p-values are shown on the graphs (b, f and h). Mann Whitney (two-tailed) test was used (d, g). Exact p-values are indicated on each graph; ns, not significant.CC BY · PubMed Central
Fig. 4 Sodium butyrate inhibited anti-CTLA-4-induced DC maturation and T cell priming. a Percentages of dendritic cells (DC defined as CD3-CD19−NKp46−CD11c+MHC-II+ among CD45+ cells) in tDLN from three pooled independent experiments. b Percentages (%) of CD80 among DC in the tDLN from pooled independent experiments. c Mean fluorescence intensity of CD86 among DC in the tDLN. d Mean fluorescence intensity (MFI) of MHC class-II among DC in the tDLN. e, f Correlation between the percentage of CD86 (e) and CD80 (f) and serum butyrate concentration in mice treated with anti-CTLA-4 (n = 12 mice) g IFNγ concentration after ex vivo restimulation of tDLN with MHC-I OVA (SIINFEKL) peptides from one representative experiment out of two independent experiments (n = 6 mice per group). p-values are indicated on each graph; Each dot represent one mouse (a, b, c, d, e, f and g). n (number of mice per group) is indicated on the graph (a, b, c and d). Bars represent mean +/− sem (a, b, c, d and g). One-way ANOVA followed by Tukey’s tests for multiple comparisons was used (a, b, c and d). Spearman test were used (e and f). Two-tailed Mann–Whitney tests were used (g). p-values are indicated on each graph; ns, not-significant.
Fig. 4 Sodium butyrate inhibited anti-CTLA-4-induced DC maturation and T cell priming. a Percentages of dendritic cells (DC defined as CD3-CD19−NKp46−CD11c+MHC-II+ among CD45+ cells) in tDLN from three pooled independent experiments. b Percentages (%) of CD80 among DC in the tDLN from pooled independent experiments. c Mean fluorescence intensity of CD86 among DC in the tDLN. d Mean fluorescence intensity (MFI) of MHC class-II among DC in the tDLN. e, f Correlation between the percentage of CD86 (e) and CD80 (f) and serum butyrate concentration in mice treated with anti-CTLA-4 (n = 12 mice) g IFNγ concentration after ex vivo restimulation of tDLN with MHC-I OVA (SIINFEKL) peptides from one representative experiment out of two independent experiments (n = 6 mice per group). p-values are indicated on each graph; Each dot represent one mouse (a, b, c, d, e, f and g). n (number of mice per group) is indicated on the graph (a, b, c and d). Bars represent mean +/− sem (a, b, c, d and g). One-way ANOVA followed by Tukey’s tests for multiple comparisons was used (a, b, c and d). Spearman test were used (e and f). Two-tailed Mann–Whitney tests were used (g). p-values are indicated on each graph; ns, not-significant.CC BY · PubMed Central
Fig. 5 Baseline immunological markers according to serum butyrate or propionate levels. a, b Mean (SEM) percentage of blood Treg (FoxP3+ among CD4+ T cells; a) and mean (SEM) sCD25 (b) according to median concentration of serum butyrate (left panel) and propionate (right panel) concentrations before ipilimumab treatment (V1). c, d Pearson correlations between butyrate and propionate quantification in serum and percentages of peripheral Treg (c; n = 38) and sCD25 (d; n = 30) before ipilimumab treatment (V1). e Mean (SEM) percentage of Treg in human PBMC (n = 8) after 4 days of culture with or without anti-CD3 and escalating concentrations of butyrate. f Mean (SEM) concentrations of systemic TNFa (left panel) and MCP-1 (right panel) according to median concentration of serum butyrate. g Mean (SEM) of systemic TNFa (left panel) and MCP-1 (right panel) according to median concentration of serum propionate. h Mean (SEM) TNFa (left panel) and MCP-1 (right panel) secretions by human PBMC (n = 4) stimulated during 4 days with or without anti-CD3 and escalating concentrations of butyrate. i Spearman correlation between butyrate (left panel) and propionate (right panel) quantifications in the stool and zonulin in the serum from patients (n = 9, where both data were available) before ipilimumab treatment (V1). j Spearman correlation between zonulin and serum concentrations of TNFa (light gray squares) and MCP-1 (black squares) (n = 12, where both data were available). Each dot represents one patient; n (number of patients) are indicated on each graph otherwise stated in the legend. P-values are indicated on each graph; Two-tailed unpaired t test (a, b, f, g) and two-way RM ANOVA followed by Tukey’s tests for multiple comparisons was used (e and h). ns, not significant.
Fig. 5 Baseline immunological markers according to serum butyrate or propionate levels. a, b Mean (SEM) percentage of blood Treg (FoxP3+ among CD4+ T cells; a) and mean (SEM) sCD25 (b) according to median concentration of serum butyrate (left panel) and propionate (right panel) concentrations before ipilimumab treatment (V1). c, d Pearson correlations between butyrate and propionate quantification in serum and percentages of peripheral Treg (c; n = 38) and sCD25 (d; n = 30) before ipilimumab treatment (V1). e Mean (SEM) percentage of Treg in human PBMC (n = 8) after 4 days of culture with or without anti-CD3 and escalating concentrations of butyrate. f Mean (SEM) concentrations of systemic TNFa (left panel) and MCP-1 (right panel) according to median concentration of serum butyrate. g Mean (SEM) of systemic TNFa (left panel) and MCP-1 (right panel) according to median concentration of serum propionate. h Mean (SEM) TNFa (left panel) and MCP-1 (right panel) secretions by human PBMC (n = 4) stimulated during 4 days with or without anti-CD3 and escalating concentrations of butyrate. i Spearman correlation between butyrate (left panel) and propionate (right panel) quantifications in the stool and zonulin in the serum from patients (n = 9, where both data were available) before ipilimumab treatment (V1). j Spearman correlation between zonulin and serum concentrations of TNFa (light gray squares) and MCP-1 (black squares) (n = 12, where both data were available). Each dot represents one patient; n (number of patients) are indicated on each graph otherwise stated in the legend. P-values are indicated on each graph; Two-tailed unpaired t test (a, b, f, g) and two-way RM ANOVA followed by Tukey’s tests for multiple comparisons was used (e and h). ns, not significant.CC BY · PubMed Central
Fig. 6 Immune markers during the course of ipilimumab. a t-SNE map of markers included in the T cell 1 panel in all patients (n = 8). b t-SNE map with the gating of T cell (CD3+) populations: CD4+ T cells (red outline), CD8+ T cells (blue outline), black outlines (regions 1: Naive CD4+ or CD8+ T cells; regions 2: Central memory CD4+ or CD8+ T cells; region 3: Effector memory CD4+ or CD8+ T cells; regions 4: Terminally effector CD4+ or CD8+ T cells). c t-SNE map at baseline (V1) and post-ipilimumab (V2-3) in patients with long-term clinical benefit (upper panel) and poor clinical benefit (lower panel). d Post-ipilimumab (V3) to baseline (V1) ratio (Ratio V3/V1;) of memory CD4+ T cells (% among CD4+ T cells) according median concentration of serum butyrate at baseline. e Serum concentration of sCD25 was monitored before ipilimumab treatment (V1) and after one or two injections of ipilimumab (V2–3) according to butyrate concentration. f As in (d) but for ICOS+CD4+ T cells (% ICOS+ among CD4+ T cells;). g sCD25 quantification in the supernatants of PBMC after 4 days of culture in medium +/− plastic-bound anti-CD3ε +/− anti-CD28 agonist with escalating dose of butyrate (n = 4). h As in (g) but ICOS mean fluorescence intensity (MFI) among CD4+T cells (n = 8). Histograms represent mean + /- sem (d, f, g and h). Each dot represents one patient. n are indicated on graphs; p-values are indicated on each graph; Wilcoxon (e) and Mann–Whitney (d, f) and two-way RM ANOVA followed by Tukey’s tests for multiple comparisons was used (g, h) tests were used. Exact p-values are indicated on each graph otherwise *p < 0.05; **p < 0.01; ***p < 0.001; ns, not significant.
Fig. 6 Immune markers during the course of ipilimumab. a t-SNE map of markers included in the T cell 1 panel in all patients (n = 8). b t-SNE map with the gating of T cell (CD3+) populations: CD4+ T cells (red outline), CD8+ T cells (blue outline), black outlines (regions 1: Naive CD4+ or CD8+ T cells; regions 2: Central memory CD4+ or CD8+ T cells; region 3: Effector memory CD4+ or CD8+ T cells; regions 4: Terminally effector CD4+ or CD8+ T cells). c t-SNE map at baseline (V1) and post-ipilimumab (V2-3) in patients with long-term clinical benefit (upper panel) and poor clinical benefit (lower panel). d Post-ipilimumab (V3) to baseline (V1) ratio (Ratio V3/V1;) of memory CD4+ T cells (% among CD4+ T cells) according median concentration of serum butyrate at baseline. e Serum concentration of sCD25 was monitored before ipilimumab treatment (V1) and after one or two injections of ipilimumab (V2–3) according to butyrate concentration. f As in (d) but for ICOS+CD4+ T cells (% ICOS+ among CD4+ T cells;). g sCD25 quantification in the supernatants of PBMC after 4 days of culture in medium +/− plastic-bound anti-CD3ε +/− anti-CD28 agonist with escalating dose of butyrate (n = 4). h As in (g) but ICOS mean fluorescence intensity (MFI) among CD4+T cells (n = 8). Histograms represent mean + /- sem (d, f, g and h). Each dot represents one patient. n are indicated on graphs; p-values are indicated on each graph; Wilcoxon (e) and Mann–Whitney (d, f) and two-way RM ANOVA followed by Tukey’s tests for multiple comparisons was used (g, h) tests were used. Exact p-values are indicated on each graph otherwise *p < 0.05; **p < 0.01; ***p < 0.001; ns, not significant.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

5 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 54 references

Cited by

See all 530

Metadata

Authors
Coutzac, C., Jouniaux, J.-M., Paci, A., Schmidt, J., Mallardo, D., Seck, A., Asvatourian, V., Cassard, L., Saulnier, P., Lacroix, L., Woerther, P.-L., Vozy, A., Naigeon, M., Nebot-Bral, L., Desbois, M., Simeone, E., Mateus, C., Boselli, L., Grivel, J., Soularue, E., Lepage, P., Carbonnel, F., Ascierto, P. A., Robert, C., & Chaput, N.
Affiliations
  • Centre National de la Recherche Scientifique (FR)
  • Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale" (IT)
  • Institut Gustave Roussy (FR)
  • AgroParisTech (FR)
  • Université Paris-Saclay (FR)
Corresponding author
Chaput, Nathalie
Venue
Nature Communications
Published
2020-05-01
Volume
11
Issue
1
Pages
2168-2168
ISSN
2041-1723 (ISSN-L)
OpenAlex
W3022450273
Cited by
513
References
54
Citations by year
2026: 89 · 2025: 105 · 2024: 84 · 2023: 86 · 2022: 74 · 2021: 58 · 2020: 17
FWCI
21.22
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature Communications (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • HAL (submittedVersion, cc-by)
  • HAL (submittedVersion)
  • RePEc: Research Papers in Economics (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • Agence Nationale de la Recherche (ANR-10-IBHU-0001)
  • Institut National de la Santé et de la Recherche Médicale (INCa-DGOS-INSERM_12551)
  • Centre National de la Recherche Scientifique (INCa-DGOS-INSERM_12551)
  • Institut National Du Cancer (INCa-DGOS-INSERM-6043, INCa-DGOS-INSERM-12551, ANR-10IBHU-0001, 2012-1-RT-14-IGR-01)
  • Institut Gustave-Roussy
  • Direction Générale de l’offre de Soins
  • Fondation Gustave Roussy
Topics
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
  • Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
Keywords
short-chain fatty acids, butyrate, propionate, CTLA-4 blockade, immune checkpoint inhibitors, gut microbiota, cancer immunotherapy resistance, regulatory T cells, dendritic cells, ICOS, memory T cells, ipilimumab, interleukin-2, cancer immunotherapy
MeSH terms
Gastrointestinal Microbiome, Ipilimumab, Animals, Butyrates, Dendritic Cells, Fatty Acids, Volatile, Humans, Mice, Inbred BALB C, Neoplasms, Propionates, RNA, Ribosomal, 16S, T-Lymphocytes, Biomarkers, Tumor, B7-1 Antigen, T-Lymphocytes, Regulatory, Mice, B7-2 Antigen, CTLA-4 Antigen

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Systemic short chain fatty acids limit antitumor effect of CTLA-4 blockade in hosts with cancer. https://app.cochat.ai/papers/10.1038/s41467-020-16079-x
The paper
Coutzac, C., Jouniaux, J.-M., Paci, A., Schmidt, J., Mallardo, D., Seck, A., Asvatourian, V., Cassard, L., Saulnier, P., Lacroix, L., Woerther, P.-L., Vozy, A., Naigeon, M., Nebot-Bral, L., Desbois, M., Simeone, E., Mateus, C., Boselli, L., Grivel, J., . . . Chaput, N. (2020). Systemic short chain fatty acids limit antitumor effect of CTLA-4 blockade in hosts with cancer. Nature Communications. https://doi.org/10.1038/s41467-020-16079-x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.